Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand

Hasib Ahmadzai, Shuying Huang, Chris Steinfort, James Markos, Roger KA Allen, Denis Wakefield, Margaret Wilsher and Paul S Thomas
Med J Aust 2018; 208 (11): . || doi: 10.5694/mja17.00610
Published online: 7 May 2018



  • Sarcoidosis is a systemic disease of unknown aetiology, characterised by non-caseating granulomatous inflammation. It most commonly manifests in the lungs and intrathoracic lymph nodes but can affect any organ.
  • This summary of an educational resource provided by the Thoracic Society of Australia and New Zealand outlines the current understanding of sarcoidosis and highlights the need for further research.
  • Our knowledge of the aetiology and immunopathogenesis of sarcoidosis remains incomplete.
  • The enigma of sarcoidosis lies in its immunological paradox of type 1 T helper cell-dominated local inflammation co-existing with T regulatory-induced peripheral anergy.
  • Although specific aetiological agents have not been identified, mounting evidence suggests that environmental and microbial antigens may trigger sarcoidosis.
  • Genome-wide association studies have identified candidate genes conferring susceptibility and gene expression analyses have provided insights into cytokine dysregulation leading to inflammation.
  • Sarcoidosis remains a diagnosis of exclusion based on histological evidence of non-caseating granulomas with compatible clinical and radiological findings.
  • In recent years, endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal lymph nodes has facilitated the diagnosis, and whole body positron emission tomography scanning has improved localisation of disease.
  • No single biomarker is adequately sensitive and specific for detecting and monitoring disease activity.
  • Most patients do not require treatment; when indicated, corticosteroids remain the initial standard of care, despite their adverse side effect profile.
  • Other drugs with fewer side effects may be a better long term choice (eg, methotrexate, hydroxychloroquine, azathioprine, mycophenolate), while tumour necrosis factor-α inhibitors are a treatment option for patients with refractory disease.


  • 1 Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW
  • 2 Geelong Hospital, Geelong, VIC
  • 3 Launceston General Hospital, Launceston, TAS
  • 4 Wesley Medical Centre, Brisbane, QLD
  • 5 UNSW Sydney, Sydney, NSW
  • 6 Auckland District Health Board, Auckland, NZ
  • 7 University of Auckland, Auckland, NZ


Competing interests:

No relevant disclosures.

  • 1. Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG), adapted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 1999; 160: 736-755.
  • 2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165.
  • 3. Gillman A, Steinfort C. Sarcoidosis in Australia. Intern Med J 2007; 37: 356-359.
  • 4. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis - environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170: 1324-1330.
  • 5. Rossman MD, Kreider ME. Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis). Proc Am Thorac Soc 2007; 4: 453-456.
  • 6. Ahmadzai H, Wakefield D, Thomas PS. The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques. Inflammopharmacology 2011; 19: 55-68.
  • 7. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013; 50: 290-297.
  • 8. Gupta D, Agarwal R, Agarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J 2007; 30: 508-516.
  • 9. Chen ES, Wahlström J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181: 8784-8796.
  • 10. Oswald-Richter K, Beachboard DC, Zhan X, et al. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res 2010; 11: 161.
  • 11. Ahmadzai H, Cameron B, Chui JJ, et al. Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respir Med 2012; 106: 701-709.
  • 12. Rappl G, Pabst S, Riemann D, et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011; 140: 71-83.
  • 13. Taflin C, Miyara M, Nochy D, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009; 174: 497-508.
  • 14. Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66: 144-150.
  • 15. Ten Berge B, Paats MS, Bergen IM, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology 2012; 51: 37-46.
  • 16. Ahmadzai H, Thomas PS, Wakefield D. Laboratory investigations and immunological testing in sarcoidosis. In: Eishi Y, editor. Sarcoidosis. Intech Open Access Publishing, 2013; pp 201-237.
  • 17. Loke WS, Herbert C, Thomas PS. Sarcoidosis: immunopathogenesis and immunological markers. Int J Chronic Dis 2013; 2013: 928601.
  • 18. Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 2008; 29: 445-458.
  • 19. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
  • 20. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
  • 21. Moller DR. Pulmonary fibrosis of sarcoidosis: new approaches, old ideas. Am J Respir Cell Mol Biol 2003; 29(3 Suppl): S37-S41.
  • 22. Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177: 330-336.
  • 23. Criado E, Sanchez M, Ramirez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics 2010; 30: 1567-1586.
  • 24. Zappala CJ, Desai SR, Copley SJ, et al. Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data. Chest 2014; 145: 101-107.
  • 25. Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2: 123-130.
  • 26. Mostard RL, van Kroonenburgh MJ, Drent M. The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med 2013; 19: 538-544.
  • 27. Bilaçeroğlu S, Perim K, Günel O, et al. Combining transbronchial aspiration with endobronchial and transbronchial biopsy in sarcoidosis. Monaldi Arch Chest Dis 1999; 54: 217-223.
  • 28. Tremblay A, Slather DR, MacEachern P, et al. A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis. Chest 2009; 136: 340-346.
  • 29. Wahlström J, Berlin M, Sköld CM, et al. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax 1999; 54: 339-346.
  • 30. Wong M, Yasufuku K, Nakajima T, et al. Endobronchial ultrasound: new insight for the diagnosis of sarcoidosis. Eur Respir J 2007; 29: 1182-1186.
  • 31. Ishikawa M, Nagai S, Akiguchi I. Neurosarcoidosis. In: Baughman RP, editor. Lung biology in health and disease - sarcoidosis. New York: Taylor and Francis, 2006; pp 505-514.
  • 32. Nunes H, Freynet O, Naggara N, et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010; 31: 428-441.
  • 33. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J 2008; 38: 270-277.
  • 34. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933-941.
  • 35. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-1977.
  • 36. Lee NJ, Lee B, Litt H. Cardiac MRI vs. myocardial 18F-FDG PET/CT in patients with clinical concern for cardiac sarcoid. J Cardiovasc Magn Reson 2015; 17(Suppl 1): O30.
  • 37. Mantini N, Williams B Jr, Stewart J, et al. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol 2012; 35: 410-415.
  • 38. Palmero V, Sulica R. Sarcoidosis-associated pulmonary hypertension: assessment and management. Semin Respir Crit Care Med 2010; 31: 494-500.
  • 39. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
  • 40. Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Dev Ther 2013; 7: 325-338.
  • 41. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 2: CD001114.
  • 42. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 501-518.
  • 43. Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116: 424-431.
  • 44. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-688.
  • 45. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: 285-290.
  • 46. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.
  • 47. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197.
  • 48. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66.
  • 49. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19: 545-561.
  • 50. Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2: 107-113.
  • 51. Müller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
  • 52. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76: 1168-1172.
  • 53. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148: 147-148.
  • 54. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48.
  • 55. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150.
  • 56. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802.
  • 57. Rossman MD, Newman LS, Baughman RP, et al. A double blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208.
  • 58. Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765-773.
  • 59. Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184: 1214-1216.
  • 60. Milman N, Graudal N, Loft A, et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012; 6: 238-247.
  • 61. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol 2014; 77: 704-714.
  • 62. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8: 95-103.
  • 63. Baughman RP, Lower EE. Medical therapy of sarcoidosis. Semin Resp Crit Care Med 2014; 35: 391-406.
  • 64. Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 91-107.
  • 65. Ahmadzai H, Kiernan MC, Wakefield D, Thomas PS. Treatment of refractory neurosarcoidosis with TNF-inhibitors: what lies ahead? Intern Med J 2012; 42: 232.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.